If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

Pfizer's (NYSE:PFE) stock is up by 4.7% over the past three months. Given that the markets usually pay for the long-term ...

Pfizer stock has been a weak performer, declining by about 7% through 2025. Things could remain mixed over 2026 as well, with the company guiding for revenues of $59.5-$62.5 billion and adjusted EPS ...

This big pharma stock still faces significant challenges in the new year.

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...

Pfizer PFE stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations. Pfizer expects total revenues for 2026 ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, making them direct peers in the blue-chip healthcare space. Both companies ...